AstraZeneca/£AZN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
- Ticker
- £AZN
- Sector
- Health
- Primary listing
- LSE
- Employees
- 96,100
- Headquarters
- Cambridge, United Kingdom
- Website
- www.astrazeneca.com
AstraZeneca Metrics
BasicAdvanced
£185B
23.66
£5.03
0.21
£2.39
2.01%
Price and volume
Market cap
£185B
Beta
0.21
52-week high
£157.32
52-week low
£98.92
Average daily volume
2.9M
Dividend rate
£2.39
Financial strength
Current ratio
0.886
Quick ratio
0.664
Long term debt to equity
0.516
Total debt to equity
0.642
Dividend payout ratio (TTM)
45.73%
Interest coverage (TTM)
10.64%
Profitability
EBITDA (TTM)
15,256.609
Gross margin (TTM)
81.69%
Net profit margin (TTM)
17.02%
Operating margin (TTM)
24.42%
Effective tax rate (TTM)
16.95%
Revenue per employee (TTM)
£482,200
Management effectiveness
Return on assets (TTM)
8.21%
Return on equity (TTM)
21.96%
Valuation
Price to earnings (TTM)
23.656
Price to revenue (TTM)
3.991
Price to book
3.67
Price to tangible book (TTM)
-21.43
Price to free cash flow (TTM)
39.189
Free cash flow yield (TTM)
2.55%
Free cash flow per share (TTM)
3.038
Dividend yield (TTM)
2.01%
Growth
Revenue change (TTM)
8.61%
Earnings per share change (TTM)
25.84%
3-year revenue growth (CAGR)
11.32%
10-year revenue growth (CAGR)
9.81%
3-year earnings per share growth (CAGR)
19.13%
10-year earnings per share growth (CAGR)
14.33%
3-year dividend per share growth (CAGR)
3.66%
10-year dividend per share growth (CAGR)
1.44%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Analyst projections of the future price of AstraZeneca stock.
Bulls say / Bears say
AstraZeneca delivered solid first-half momentum: revenue rose 6% at constant exchange rates and core EPS increased 11%, while management retained its full-year targets of mid-to-high single-digit revenue growth and low double-digit EPS growth. (AstraZeneca)
Tozorakimab produced positive results in two Phase III COPD trials, reducing exacerbations across a broad patient population. Its US application has priority review, and the company sees peak sales above $5 billion across indications. (AstraZeneca, CNBC)
The growth engine remains diversified rather than dependent on one launch: oncology revenue grew 15% and rare-disease revenue 11% in the first half, alongside six positive Phase III programmes and eight first approvals in major markets. (AstraZeneca)
Mature products are already facing erosion: Farxiga lost US exclusivity, while Chinese volume-based procurement pressured sales. These headwinds contributed to a 5% decline in BioPharmaceuticals revenue in the first half and a 12% fall in cardiovascular, renal and metabolic sales. (AstraZeneca)
Recent development setbacks show that the pipeline carries meaningful execution risk. AstraZeneca reported a disappointing CARDIO-TTRansform outcome, an Ultomiris Phase III miss and the cancellation of two internal ADC candidates, while management put Phase III success at around 60%, below its historic level. (Fierce Pharma, AstraZeneca)
Data summarised monthly by Lightyear AI. Last updated on 26 Sept 2026.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AstraZeneca
AllEURGBPUSD
Fund name | Fund size | £AZN weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 13.91% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 13.91% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 13.58% |
iShares Core FTSE 100€ISFA | €19B | 7.07% |
iShares Core FTSE 100£CUKX | £3.2B | 7.07% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.